Friday, November 20, 2026

New antibody ‘engagers’ could transform autoimmune treatments, an alternative to CAR T cells

Good news! This seems to be an interesting subject, but the two sources cited here are rather inadequate I am afraid. AAAS did a poor job with these two articles!

"Some have hailed CAR T cells as a revolutionary treatment for autoimmune diseases, but these genetically engineered immune cells have a dark side: They can cause dangerous side effects as show by several deaths in recent clinical trials. So, some researchers looking for a safer—as well as simpler and cheaper—alternative are turning to engineered antibodies called T cell engagers, with dozens of trials of them in lupus, rheumatoid arthritis, and other conditions already underway.

CAR T cells quell autoimmunity by killing the B cells that make self-reactive antibodies;
T cell engagers do the same. But instead of infusing a person with engineered T cells that take weeks to make, off-the-shelf T cell engagers can be injected into a person’s blood, where they connect existing T cells to B cells so the former destroy the latter.
These engagers have already produced extended remissions in some patients. ..."

"... T cell engagers, labmade antibodies that coax ordinary T cells to kill troublemaking B cells. ...

A jolt of encouragement came in September, when scientists reported results from a phase 1 trial in 12 people with lupus. The engager they tested, A-319, spurred no serious side effects and quelled symptoms in some recipients for at least a year, the researchers revealed in Nature Medicine. ...

More than 50 other clinical trials are now assessing T cell engagers in autoimmune illnesses. ... In May, the Belgian pharma company UCB shelled out $2 billion for a biotech whose T cell engager is being tested in several clinical trials. And Gilead Sciences paid more than $3.5 billion this year to buy one T cell engager company and license another’s products.  ..."

ScienceAdviser

No comments: